Member Info for JoeyDiamond

Alarming problem for many of the younger generation who like to vape thinking it safe. From Prions lancet article posted. That may be a big burden on the NHS in future years.

Vaping or e-cigarette use
Use of e-cigarettes impairs the body's ability to fight infections by reducing the antimicrobial activity of alveolar macrophages, neutrophils, and epithelial cells and by reducing the expression of immune-related genes. Use of e-cigarettes alters more than 200 proteins in airway epithelial cells; the effects on 113 of these proteins are unique to e-cigarette use.
E-cigarette use can promote lung inflammation and is associated with respiratory symptoms such as cough, sputum production, and wheezing. In an analysis in which combustible tobacco use was controlled for, e-cigarette use was independently associated with chronic respiratory diseases, including asthma and COPD. The risk of developing COPD from combustible cigarettes is doubled when combined with e-cigarette use, and use of e-cigarettes in never-tobacco-smokers doubles or triples the risk of self-reported COPD, emphysema, or chronic bronchitis. Additional studies are needed to confirm the direct effect of e-cigarettes on the development of COPD, but the available data are compelling and concerning.

Ever wondered why Flu all but disappeared during winter whilst we had Covid dominating? This paper suggests one of the reasons why.

https://www.biorxiv.org/content/10.1101/2022.09.06.506799v1.full.pdf

The Omicron-induced interferon response generated an antiviral state that protected infected cells from super-infection with influenza A viruses. In summary, we show that BA.1 and BA.5 (but not Delta) induce a functionally relevant pronounced interferon response that suppresses influenza A virus replication.

This is a come get me pitch for a platform trial. No longer just evidence of antiviral or AAbs or synergy with other drugs. We now have another avenue to explore of secondary bacterial infections.

So there are 4 distinct areas to be explore combined with an excellent and proven safety record makes the drug an easy candidate to select for a platform trial IMO. It meets all STRIVEs selection criteria for example.

Just been reading up on the Argentina outbreak 6/11 have now died, thats over 50% mortality rate!

Legionella pneumophila is the reported culprit. Legionella bacteria can cause a serious type of pneumonia (lung infection) called Legionnaires’ disease.

https://www.cdc.gov/legionella/about/index.html

I am theorising this new form of Legionella bacteria may be resistant to antibiotics.

Definately a fantastic much needed trial, and definately worth Synairgen supporting. The data will indeed be of great benefit to all pharma companies.

Interestingly blood samples to be taken so will be a great database to look for things like autoantibodies for example. Something SNG should have done in their Sprinter trial :-0

That article Hold posted isn't a great study for a number of reasons. Survivorship bias is a key issue plus we do not know what these people were admitted to hospital for (were they in for a stroke and happened to catch Covid in hospital?) These obvious confounders can skew results considerably so as the authors of the study say this is just an estimate! Maybe the article is omitting key information I couldn't verify as no link to the study.

That said other studies have shown that SARS-COV-2 can cause damage to other organs in the body so the elevated risks of a multitude of further afflictions are true from (repeat) infection.

I don't understand why people claim it must be down only to Covid infections or NHS reduced function or it must be just from vaccine side effects. Its pretty obvious by now that all 3 reasons are true and are contributing to excess illness/mortality.

Wigster the groups are closed however if you ask the relevent admin of each site they can invite you.

Reddit has a limit of 250 members iirc so it may not be possible for an invite if they are already full.

Hi Aether, yes there is a big relevance.

There has been a flurry of science papers doing similar experiments in recent times showing that SARS-COV-2 is becoming more resistant to both Paxlovid and Molnupirivir. Prior to these drugs being approved we discussed at length here what feels a long time ago, that this resistance was to be fully expected. The other worry was these drugs may influence new mutations in the virus rendering the drugs ineffective like the many MaBs before them . With this in mind it would make sense to prolong the sales/shelf life of these multi-billion drugs.

A recent example looking at Paxlovid resistance.
https://www.biorxiv.org/content/10.1101/2022.08.07.499047v2

With this in mind there have been numerous studies from different countries looking into combining drugs with Paxlovid and Molnupirivir. In all of these studies they found using interferon Beta in combination with with either Molnupirivir or Paxlovid had a more effective anti-viral effect than using Paxlovid or Molnupirivir alone.

Recent example of this synergism of interferon-beta with antiviral drugs.
https://doi.org/10.1016/j.jinf.2022.07.023

So like the autoantibodies science there are other important science pathways Interferon-Beta can be suggested as a good choice for inclusion on numerous platform trials.

The new platform trial is definately one to watch due to start in Novemeber 1st. One of the problems is what drugs are already planned to be included. Our friend Dexamethasone :(

SNG001 would need to be added at the onset of this trial as to not be mixed up with standard of care (which likely Dex will be)

Billy to my knowledge STRIVE isn't off the ground yet and no drugs have been selected. With the US political landscape and regulatory bodies like CDC changing their views on Covid significantly in the last few days I fear the trial could be shelved.

they may decide its not worth it if the subset of patients is too small.

Doc from the activ-2 trial design they were aware of autoantibodies research and it was something they were going to record for SNG's arm of the trial. This all links to Casanova and colleagues work on inborn errors and autoantibody discoveries most of us are well aware of on this board.

So yes the data obtained will belong to NIH/NAID etc and they will own the blood samples to perform other analysis if they see fit.

We can only hope they decide to progress down this new science road but at the same time

The actual activ-2 topline data results will be welcome.

As some allude to already is some of us are hoping the delay is due to a sub analysis of looking for autoantibodies to type 1 interferon from the patients blood samples and a positive correlation in treating these people with interferon beta.

Hopefully a new subset of patients can be found adding substance and reason to trial IFN-B in a confirmatory trial (like Strive)

He is stepping down now as he knows the GOP after the mid terms would fire him. They will launch an investigation and hopefully criminal charges.

Hearing strong rumours that in the next week or so an outpatient drug on the activ trials will post some good results.

Most likely be Fluvoxamine on the activ-6 trial but you never know could be something on activ-2.

Just to tag on the bottom of this Molnupirivir and Paxlovid there are big worries now from many studies showing the virus is becoming more resistant to these drugs. Possible these companies may look at combination therapy to prolong their shelf life?

Another rceent Paxlovid resistance paper
https://www.biorxiv.org/content/10.1101/2022.08.07.499047v1

Some positive news for interferon beta. A study tested using interferon Beta in combination with with Molnupirivir, Paxlovid and Aprotinin. A drug combination with interferon had a more effective anti-viral effect than using the drugs alone.

https://doi.org/10.1016/j.jinf.2022.07.023

conclusion, even closely related SARS-CoV-2 (sub)variants can differ in their biology, as indicated by different BA.1 and BA.2 replication kinetics, and in their response to antiviral treatments, as indicated by differences in the virus responses to betaferon, EIDD-1931/ molnupiravir, and aprotinin and differing levels of synergism of betaferon combinations with other antiviral drugs. Betaferon combinations with nirmatrelvir and, in particular, with EIDD-1931 and aprotinin displayed high levels of synergism, which makes them strong candidates for clinical testing.

An easier read news story here

https://www.kent.ac.uk/news/science/32148/kent-researchers-help-future-proof-covid-19-treatments

The findings revealed that interferon combination with molnupiravir, nirmatrelvir, and aprotinin were much more effective than interferon combinations with remdesivir. This may explain, why remdesivir/ interferon combinations have so far shown limited improvement compared to remdesivir alone. Moreover, interferon combinations with the other three drugs should be tested in the clinics.

Professor Jindrich Cinatl (Goethe-University and Dr Petra Joh Research Institute) added: ‘If these findings are confirmed in patients, I hope that more effective therapies will help us to reduce the formation of novel dangerous COVID-19 variants.’

Interferon a-2b nasal spray shortened viral shedding time of SARS-CoV-2 Omicron variant

https://www.frontiersin.org/articles/10.3389/fimmu.2022.967716/full

Another Interferon a-2b nasal spray study out of Shanghai China with positive results. Cheap to buy so worth ordering some to squirt up your nose if you test positive :)

It amazes me how many people are just so brainwashed by the media that you can’t say anything negative about the vaccines even when there is actual evidence saying otherwise!

BS post you say? I’ve linked 2 factual sources to a science paper and some medical researchers on Twitter. 2 of the 300 kids in the study had to be admitted to hospital.

How many kids end up with Covid induced myocarditis? Denmark did a study and results were 0/74611.

The risk/benefit calculation has drastically changed which is why Denmark have changed policy and no longer allow u18s the vaccine.